Category: Intellectual property
-
AbbVie, Galapagos Partner on Cystic Fibrosis Therapies
The pharmaceutical companies AbbVie in North Chicago, Illinois and Galapagos NV in Mechelen, Belgium are collaborating on development and marketing of treatments for the inherited disease cystic fibrosis. The deal, with a total potential value of at least $405 million, covers discovery, development, and commercialization of compounds addressing defective genetic mutations associated with the disease.…
-
University of Houston Spins-Off Nanotech Coatings Company
A physics professor at University of Houston in Texas started a company to develop and manufacture protective coatings for industrial and consumer goods based on his research in nanotechnology. C-Voltaics, started by Houston physicist Seamus Curran, was awarded last week the Young Technology Award at the Commercialization of Micro- and Nanosystems conference in The Netherlands, according…
-
U.S. University Research Commercialization Gains in 2012
American universities and research institutes report more research discoveries headed toward the marketplace in their 2012 fiscal year, with increases in discoveries disclosed, patents, licenses and licensing income, and start-up companies formed. The Association of University Technology Managers (AUTM), the group representing campus technology transfer specialists, released today highlights of its annual survey for institutions’…
-
Bayer, Compugen to Partner on Cancer Immunotherapies
The pharmaceutical company Bayer HealthCare in Berlin and drug discovery company Compugen Ltd in Tel Aviv, Israel agreed on a development and licensing deal for two potential cancer therapies discovered by Compugen that harness the body’s immune system. The deal has a potential value to Compugen of at least $540 million. Compugen uses computational biology,…
-
FibroGen, AstraZeneca Partner on Kidney-Based Anemia Therapy
The global pharmaceutical company AstraZeneca is licensing a therapy for anemia caused by kidney disease made by FibroGen, a biotechnology company in San Francisco. The deal is valued initially at $815 million, and covers the U.S., China, and other markets not covered by an earlier FibroGen license to Astellas Pharma for commercialization in Europe, Japan,…
-
Scripps Institute, Sigma-Aldrich to Partner on Reagents
Scripps Research Institute in La Jolla, California is collaborating with Sigma-Aldrich Corp. in St. Louis to speed the availability of new chemical reagents for drug discovery to the scientific community. The deal calls for payments to Scripps from Sigma-Aldrich, a chemical and laboratory services company, although the size of the payments is not disclosed. Under…
-
Biotech, Cancer Center Partner on Tumor-Targeting Peptides
Blaze Bioscience, a biotechnology company in Seattle, is partnering with the Fred Hutchinson Cancer Research Center, also in Seattle, to develop and commercialize drug candidates based on engineered peptides that better target tumor cells than conventional cancer drugs. Financial amounts in the agreement were not disclosed. The Hutchinson Center is conducting research on optides —…
-
University Patents, Licenses Cattle Feed Supplement
Kansas State University in Manhattan received a patent and licensed a nutritional supplement for cattle feed developed by one of its faculty members. Research by animal sciences professor Jim Drouillard led to development of a supplement that improves absorption of omega-3 fatty acids beneficial to livestock, which Kansas State patented earlier this year and licensed…
-
GSK Licenses Biotech Antibody for Arthritis, MS Drugs
The biotechology company MorphoSys AG in Germany says the pharmaceutical company GlaxoSmithKline is licensing its targeted human antibody drug candidate MOR103 to treat rheumatoid arthritis. The deal has a potential value to MorphoSys of €445.5 million ($US 579 million), not counting future sales royalties. MorphoSys develops engineered antibodies for therapies and diagnostics. One of its…
-
Purdue Licenses Reagent for Safer Fluorine Compounds
Purdue University in Indiana licensed a reagent developed and patented by one of its organic chemists that makes it safer and more environmentally friendly to add fluorine to organic compounds. The university licensed the reagent, developed in Purdue’s chemistry and pharmacology labs under the direction of professor David Colby, to Aldrich Chemical Co., a subsidiary of…